Kaken Pharmaceutical (4521) Q4 2026 earnings summary

Executive summary

• FY2025 saw a significant decline in net sales and profits, mainly due to the Clenafin patent cliff, deferred milestone payments, and increased strategic investment.

• Net sales declined 18.3% year-over-year to ¥76,871 million for the fiscal year ended March 31, 2026.

• Operating profit fell from ¥21,034 million to ¥899 million; net profit declined 84.6% to ¥2,144 million.

• Strategic focus remained on pipeline expansion, global product launches, and cost of capital management.

• Major product launches included Ekterly and Ecclock in new markets, and the acquisition of Aadi expanded the overseas portfolio.

Financial highlights

• Gross profit decreased to ¥39,991 million from ¥58,532 million year-over-year, a 31.7% decline.

• R&D expenses rose 9.9% to ¥20,585 million, reflecting pipeline advancement.

• Selling, general and administrative expenses rose to ¥40,891 million from ¥37,497 million year-over-year.

• Extraordinary income rose to ¥3,511 million, mainly from gains on sales of investment securities and non-current assets.

• Cash and cash equivalents at year-end were ¥50,705 million, down ¥19,380 million from the prior year.

Outlook and guidance

• FY2026 net sales are forecast to rise 16.9% to ¥89,900 million, with operating profit expected to recover to ¥7,900 million.

• Profit is projected to increase to ¥6,500 million, driven by new product launches and full-year consolidation of Aadi.

• Basic EPS forecast for FY2027 is ¥171.65.

• Dividend forecast for FY2027 is ¥190 per share.

• R&D and SG&A expenses will continue to grow, supporting global expansion and pipeline progress.